Edwards Lifesciences price target raised to $73 from $70 at Piper Sandler

Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $73 from $70 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 results, posting a modest top-line beat with adjusted EPS coming in ahead of Street models. Regarding guidance, Edwards Lifesciences reiterated its previous top-line and adjusted EPS guidance for 2025 and issued Q1 guidance that bracketed the Street on both the top and bottom-line. Bigger picture, Piper still views the high-end of full year guide as a bit steep and takes a wait-and-see approach particularly as it relates to TAVR.